CELEX: 62014TB0511
Language: en
Date: 2017-10-25 00:00:00
Title: Case T-511/14: Order of the General Court of 25 October 2017 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Zoledronic acid Teva Generics — Zoledronic acid — Period of protection of the medicinal product Aclasta containing the active substance zoledronic acid — Withdrawal of the contested measure — No need to adjudicate)

8.1.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 5/42
            
         Order of the General Court of 25 October 2017 — Novartis Europharm v Commission
   (Case T-511/14) (1)
   
   ((Medicinal products for human use - Marketing authorisation for the medicinal product Zoledronic acid Teva Generics - Zoledronic acid - Period of protection of the medicinal product Aclasta containing the active substance zoledronic acid - Withdrawal of the contested measure - No need to adjudicate))
   (2018/C 005/56)
   Language of the case: English
   
      Parties
   
   
      Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
   
      Defendant: European Commission (represented by: A. Sipos and M. Wilderspin, Agents)
   
      Re:
   
   Action brought under Article 263 TFEU seeking annulment of Commission Implementing Decision C(2014) 2155 final of 27 March 2014 granting a marketing authorisation to Teva Generics BV for the medicinal product for human use Zoledronic acid Teva Generics — Zoledronic Acid under Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).
   
      Operative part of the order
   
   
               1.
            
            
               There is no longer any need to adjudicate on the action.
            
         
               2.
            
            
               There is no longer any need to adjudicate on Teva BV’s application for leave to intervene.
            
         
               3.
            
            
               Each party shall bear its own costs.
            
         
      (1)  OJ C 388, 3.11.2014.